COPY

BEFORE THE BOARD OF MEDICAL EXAMINERS OF THE STATE OF NEVADA

* * * * *

In The Matter of Charges and

Complaint Against

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

STEPHEN SELDON, M.D.,

Respondent.

NCase No. 08-10701 FILED Peier ber 1 CLERK OF THE BOARD

COMPLAINT AND REQUEST FOR SUMMARY SUSPENSION

The Investigative Committee of the Board of Medical Examiners of the State of Nevada, composed of Charles N. Held, M.D., Chairman, Benjamin J. Rodriquez, M.D., Member, and Jean Stoess, M.A., Member, by and through Lyn E. Beggs, General Counsel for the Nevada State Board of Medical Examiners, having a reasonable basis to believe that STEPHEN SELDON, M.D., hereinafter referred to as "Dr. Seldon", has engaged in conduct that is grounds for discipline pursuant to the provisions of NRS Chapter 630, hereby alleges, charges and complains against said Respondent as follows:

Dr. Seldon is currently licensed in active status, and was so licensed by the
 Nevada State Board of Medical Examiners, hereinafter referred to as "the Board," on
 February 2, 1995 (License No. 7343), pursuant to the provisions of Chapter 630 of the Nevada
 Revised Statutes, and at all times addressed herein was so licensed.

22

2. The Board's records show that Dr. Seldon's specialty is otolaryngology.

3. Dr. Seldon, in conjunction with his wife Deborah Martinez Seldon, operates a
medical practice called "A New You Medical Aesthetics" (hereinafter "A New You") and
currently known as "Medical Aesthetics and Cosmetic Surgery" in Henderson, Nevada,
specializing in cosmetic procedures. One of the procedures offered by Dr. Seldon through "A
New You" and now "Medical Aesthetics and Cosmetic Surgery" is the injection of botulinum
neurotoxin type A for cosmetic purposes.

OFFICE OF THE GENERAL COUNSEL Nevada State Board of Medical Examiners 1105 Terninal Way #301 Reno, Nevada 89502 (775) 688-2559 4

5

6

7

8

9

10

11

4. Botulinum neurotoxin type A has been approved by the Federal Drug
 Administration (FDA) for human use for limited purposes and the only FDA approved
 manufacturer of botulinum neurotoxin type A is Allergen, using the brand name Botox.

5. Beginning in October 2003 and through September 2005, Dr. Seldon and Mrs. Seldon began purchasing botulinum neurotoxin type A from a company called Toxin Research International, Inc. (hereinafter TRI). TRI was based in Tucson, Arizona and was not an approved manufacturer of botulinum neurotoxin type A for human use. The botulinum neurotoxin type A manufactured and sold by TRI was called TRItox. TRItox is not and has never been approved for human use, and, in fact, each vial was labeled, "For research purposes only, not for human use."

6. Despite the labeling and warnings regarding the TRItox not being for human use, Dr. Seldon administered the TRItox to patients of "A New You." Dr. Seldon did not inform the patients that he was administering TRItox to them rather than the FDA-approved Botox. In the course of conducting the business of "A New You," Dr. Seldon and "A New You" made certain representations regarding Dr. Seldon's training by Allergan, Dr. Seldon's expertise based upon that training, and Dr. Seldon's use of Botox.

7. On June 27, 2007, Dr. Seldon and Mrs. Seldon were charged by a Criminal
Indictment resultant from a federal grand jury in the case entitled *United States v. Stephen Lee Seldon, M.D. and Deborah Martinez Seldon* (U.S. Dist. Ct. Nev. Case No. 07-CR-0135-KJDLRL). In the Criminal Indictment, Dr. Seldon and Mrs. Seldon were each charged with fourteen
counts of mail fraud under 18 U.S.C. § 1341, punishable by up to twenty years in prison for each
count and one count of misbranding a drug while held for sale under 21 U.S.C. § 331(k),
punishable by up to three years in prison. (See Exhibit A)

8. On November 19, 2008, after a ten day jury trial, the jury found Dr. Seldon and
 Mrs. Seldon each to be guilty of all fifteen counts made against them in the Criminal Indictment.
 Sentencing on the convictions is scheduled for February 19, 2009. The Seldons were released on
 their own recognizance pending sentencing. (See Exhibit B)

Based on the conviction of Dr. Seldon, the Nevada State Board of Pharmacy 9. immediately suspended the controlled substance registration of Dr. Seldon pursuant to NRS 639.2121 on November 24, 2008. (See Exhibit C)

On November 7, 2008, the Investigative Committee of the Nevada State Board of 10. Medical Examiners filed a formal disciplinary complaint against Dr. Seldon alleging two counts of malpractice and one count of failure to maintain timely, legible, accurate and complete medical records relating to a patient who underwent tumescent liposuction by Dr. Seldon in October 2007. The patient at issue in that matter died less than 48 hours after undergoing the procedure. (See Exhibit D)

COUNT I

All of the above paragraphs are incorporated by reference as though fully set forth 11. herein.

NRS 630.301(1) provides that conviction of a felony relating to the practice of 12. medicine or the ability to practice medicine is grounds for initiating discipline against a licensee. 14 Dr. Seldon's recent convictions in federal court all relate to his medical practice at 15 13. "A New You" and specifically to his use of TRItox, in place of Botox, unbeknownst to his 16 17 patients.

Accordingly, Dr. Seldon has violated NRS 630.301(1) and is subject to 18 14. disciplinary action as provided by NRS 630.352. 19

COUNT II

All of the above paragraphs are incorporated by reference as though fully set forth 15. 21 22 herein.

NRS 630.301(11)(f) provides that conviction of a violation of any federal or state 23 16. law regulating the possession, distribution or use of any controlled substance or any dangerous 24 drug is ground for initiating disciplinary action against a licensee. 25

Dr. Seldon's conviction for fourteen counts of mail fraud relating to the purchase 26 17. and use of TRItox and one count of misbranding a drug while held for sale are violations of 27 /// 28

1

2

3

4

5

6

7

8

9

10

11

12

13

20

federal law and accordingly Dr. Seldon has violated NRS 630.01(11)(f) and is subject to disciplinary action as provided by NRS 630.352.

COUNT III

4 18. All of the above paragraphs are incorporated by reference as though fully set forth
5 herein.

19. NRS 630.306(7) provides that continual failure to exercise the skill or diligence or use the methods ordinarily exercised under the same circumstances by physicians in good standing practicing in the same specialty or field is grounds for initiating disciplinary action against a licensee.

20. Dr. Seldon's actions, as proven in federal court, and those alleged in the recent filing of a formal disciplinary action against him show an on-going and continual failure to exercise the skill or diligence or use the methods ordinarily exercised under the same circumstances by physicians in good standing practicing in the same specialty or field.

14 21. Accordingly, Dr. Seldon has violated NRS 630.306(7) and is subject to 15 disciplinary action as provided by NRS 630.352.

WHEREFORE, the Investigative Committee of the Nevada State Board of Medical Examiners prays as follows:

That the Nevada State Board of Medical Examiners schedule an emergency meeting 18 1. by telephone conference pursuant to NRS 241.020, and that the Board review the above Complaint, 19 with exhibits, and any other evidence, argument or presentation, find that Dr. Seldon poses a threat 20 to the health and safety of patients he sees and treats, or may see and treat, as well as the public in 21 general. He has recently been convicted of conduct in federal court that placed his patients at risk 22 and showed a substantial disregard for their safety and welfare. He faces the possibility of 23 substantial prison time, however he remains out of custody and is believed to be presently engaged 24 in the practice of medicine. Accordingly Dr. Seldon is able to engage in the same course of conduct 25 that gave rise to the federal criminal action and the formal disciplinary complaint filed by this 26 Committee and thus the Investigative Committee requests that the Nevada State Board of Medical 27 28 ///

1

2

3

6

7

8

9

10

11

12

13

16

Examiners summarily suspend Dr. Seldon's license to practice medicine in the state of Nevada, pursuant to NRS 233B.127 pending a hearing on this Complaint; and

2. That the Nevada State Board of Medical Examiners conduct a hearing on the Complaint herein as provided by statute, find and determine that Dr. Seldon has violated one or more provisions of the Medical Practice Act (NRS Chapter 630), enter findings of fact, conclusions of law, and an order imposing sanctions upon Dr. Seldon according to NRS 630.352; and

3. That the Nevada State Board of Medical Examiners take such other and further action as may be just and proper in these premises.

DATED this 1st day of December, 2008.

INVESTIGATIVE COMMITTEE OF THE NEVADA STATE BOARD OF MEDICAL EXAMINERS

Lyn E. Beggs // General Counsel and Attorney for the Investigative Committee

(775) 688-2559

VERIFICATION

STATE OF NEVADA) COUNTY OF DOUGLAS)

CHARLES N. HELD, M.D., having been duly sworn, hereby deposes and states under penalty of perjury that he is the Chairman of the Investigative Committee of the Nevada State Board of Medical Examiners that investigated the complaint against Respondent herein; that he has read the foregoing Complaint; and that based upon the results of the Investigative Committee's investigation into a complaint against Respondent, the allegations and charges in the foregoing Complaint against Respondent are true, accurate and correct.

Dated this 1st day of December 2008.

SS.

CHARLES N. HELD, M.D.

OFFICE OF THE GENERAL COUNSEL Nevada State Board of Medical Examiners 1105 Terminal Way #301 Reno, Nevada 89502 (775) 688-2559

EXHIBIT A

ĺ

(,

ç.

	FLED RECEIVED
STEVEN W. MYHRE	COUNSELENATIES OF FECCHE
Acting United States Attorney	
CRANE M. POMERANTZ Assistant United States Attorney	
333 Las Vegas Blvd., South, Suite 5000 Las Vegas, Nevada 89101	CLERN US CLEARING COLLECT DISTRICT OF GLEADA
(702) 388-6336	אוויב זה
	S DISTRICT COURT
DISTRICT	COF NEVADA
	000-
UNITED STATES OF AMERICA,) CRIMINAL INDICTMENT
PLAINTIFF,) 2:07-CR-0135-KJD-LRL
VS.) VIOLATIONS:
STEPHEN LEE SELDON, M.D and	 18 U.S.C. § 1341 - Mail Fraud 18 U.S.C. § 2- Aiding and Abetting
DEBORAH MARTINEZ SELDON,) 21 U.S.C. § 331(k) - Misbranding a Drug
DEFENDANTS.) While Held for Sale <u>18 U.S.C. § 981(a)(1)(C) - Forfeiture</u>
THE OP AND HIDLY OF A DOEC THAT.	
THE GRAND JURY CHARGES THAT:	1
At all times relevant to this Inc	
	troduction
1. Defendant STEPHEN	LEE SELDON, a medical doctor, schemed with
defendant DEBORAH MARTINEZ SELDO	ON , his wife and the manager of his medical practice,
to defraud his patients by treating them with a c	cheaper, non-FDA approved version of Botox®, a drug
used to reduce facial wrinkles. By misreprese	enting to the patients of their medical practice the true
nature of the product they were using, STEP	HEN LEE SELDON and DEBORAH MARTINEZ
SELDON enriched themselves while exposin	
	s and Entities
	DON was a physician licensed by the State of Nevada
to practice medic ne.	
to practice incore new	

Case 2:07-cr-00135-KJD-LRL

3. DEBORAH MARTINEZ SELDON was the manager of STEPHEN LEE
 SELDON'S medical practice "A New You Medical Aesthetics" ("A New You"). As the office
 manager, DEBORAH MARTINEZ SELDON'S responsibilities included ordering supplies, paying
 bills, managing personnel and managing the bank accounts at A New You.

5 4. Together, STEPHEN LEE SELDON and DEBORAH MARTINEZ 6 SELDON operated A New You in Las Vegas, Nevada. At A New You, STEPHEN LEE SELDON 7 advertised that he performed wrinkle reducing treatments using injections of Botox®, and other 8 cosmetic procedures.

9

Federal Regulation of Drugs and Biological Products

5. The FDA regulates the manufacture and distribution of drugs and biological products in the United States pursuant to the provisions of the Food, Drug and Cosmetic Act, Title 21, United States Code, Section 301, *et. seq.* (the "Act"). The FDA has established approval procedures for evaluating new drugs and licensing biological products. Approval is required for each new drug intended for human use before its introduction into interstate commerce is permitted. A license is also required for each new biological product before its introduction into interstate commerce is permitted.

6. A "drug" is defined by the Act as, among other things, any articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals; articles (other than food) intended to affect the structure or any function of the body of man or other animals; and articles intended for use as a component of any such articles. 21 U.S.C. § 321(g).

7. A "biological product" is defined as a "... toxin applicable to the prevention,
treatment, or cure of a disease or condition of human beings." 42 U.S.C. § 262(i). When a biological
product under this section also meets the definition of a "drug," as stated in Paragraph Five of this
Indictment, the "biological product" is a "drug" under 21 U.S.C. § 321(g).

25 . .

26 . .

Case 2:07-cr-00135-KJD-LKL

8. The FDA enforces drug safety and efficacy standards by guarding against the misbranding of drugs. Pursuant to 21 U.S.C. § 331(k), the doing of any act with respect to a drug, if such act is done while the drug is held for sale (whether or not the first sale) after shipment in interstate commerce results in such drug being adulterated or misbranded, and is prohibited. 21 U.S.C. § 331(k).

6 9. A drug is misbranded if, among other things, it is offered for sale under the 7 name of another drug. 21 U.S.C. § 352(i)(3).

8

Botulinum Neurotoxin Type A

9 10. The bacterium *Clostridium Botulinum* produces Botulinum Neurotoxin Type 10 A, a highly potent toxin. When present in sufficient degree in humans, Botulinum Neurotoxin Type 11 A can cause botulism. Severe botulism paralyzes its victims and can result in death unless timely 12 medical intervention occurs

Botulinum Neurotoxin Type A can be both a drug under the Act, 21 U.S.C. § 11. 13 321(g), and a biological product, 42 U.S.C. § 262(1), when the product is intended for use in the 14 diagnosis, cure, mitigation, treatment or prevention of disease in human beings, or to affect the 15 structure or the function of the human body. Therefore, no form of Botulinum Neurotoxin Type A 16 can be distributed legally in interstate commerce for use on humans unless it has been approved by 17 the FDA as a new drug (or there is in effect with the FDA a new drug application, an abbreviated new 18 drug application, or a notice of claimed exemption for an investigational new drug), or it has been 19 licensed as a biological product by the FDA. 20

21

<u>Allergan Botox®</u>

In or about December 1991, the FDA approved a biological products license for Botox®, the brand name of a drug derived from Botulinum Neurotoxin Type A, manufactured by Allergan, Inc., of Irvine, California, for the treatment of certain disorders of the muscles related to the eyes.

26 .

Case 2:07-cr-00135-KJD-Lhu

In or about April 2002, the FDA approved a supplement to Allergan's Botox®
 license application for the treatment of glabellular lines, commonly referred to as forehead wrinkles.
 Under this FDA approval, Allergan's Botulinum Neurotoxin Type A product was marketed and
 labeled for this supplemental usage as Botox® Cosmetic.

5 14. Botox® and Botox® Cosmetic (collectively "Botox®") is injected with a 6 hypodermic need e. It is used to temporarily smooth facial wrinkles. It works by paralyzing the 7 muscles that cause wrinkles. Once injected, it blocks the transmission of nerve impulses to the 8 muscles that receive the drug; this reduces the activity of the muscles that cause frown lines to form.

9 15. Botox® is the only product containing Botulinum Neurotoxin Type A 10 approved by the FDA for the treatment of glabellular lines in humans. Allergan, Inc. ("Allergan") 11 of Irvine, California is the only approved manufacturer of Botox®. Accordingly, all doctors treating 12ⁱ patients with Botulinum Neurotoxin Type A are required to use Allergan's Botox® products.

13

Toxin Research International, Inc.

16. Toxin Research International, Inc. ("TRI") was an Arizona corporation with
15 its principal place of business in Tucson, Arizona. TRI was managed and controlled by Chad Livdahl
16 ("Livdahl") and Zahra Karim ("Karim").

17 17. During 2003 and 2004, TRI, through Livdahl and Karim, marketed and sold
18 a Botulinum Neurotoxin Type A ("TRItox") that was neither approved nor licensed by FDA for use
19 on humans.

18. Although TRI marketed its TRItox to physicians and others involved in
patient treatments, it sold TRItox in vials that were labeled "For research purposes only, not for
human use."

19. TRI's sales invoices, which accompanied orders of TRItox mailed to
physicians and others involved in patient treatments, also included the warning, "For research
purposes only, not for human use."

26 .

I	20. TRI charged customers much less for its TRItox than Allergan charged			
2 ·	customers for Botox®. By using TRItox instead of Botox®, physicians and others involved in patient			
3	treatments could increase their profits on each treatment.			
4	<u>COUNTS ONE THROUGH FOURTEEN</u> (Mail Fraud)			
5				
6	21. The Grand Jury incorporates by reference the allegations in Paragraphs One			
7	through Twenty, above, as though fully set forth herein.			
8	22. From on or about October 15, 2003, until on or about September 16, 2005,			
9	in the State and Federal District of Nevada, and elsewhere,			
10	STEPHEN LEE SELDON, MD and DEBORAH MARTINEZ SELDON,			
11	DEDORAH MARTINEE OBADON,			
12	defendants herein, aided and abetted by each other, did devise and intend to devise a scheme and			
13	artifice to defraud, and for obtaining money and property by means of false and fraudulent pretenses,			
14	representations and promises, which scheme and artifice involved fraudulently obtaining money from			
15	patients by substituting cheaper, non-FDA approved TRItox in treatments provided to patients at A			
16	New You, while falsely and fraudulently representing to the patients that they were receiving			
17	injections of the more expensive, FDA-approved Botox®.			
18	Scheme and Artifice to Defraud			
19	23. It was part of the scheme and artifice that STEPHEN LEE SELDON and			
20	Deborah Martinez Seldon defrauded patients by misleading them to believe that they were receiving			
21	the FDA-approved drug Botox®, when, in fact, the patients were receiving TRItox, which was not			
22	FDA-approved and exposed the patients to severe health risks.			
23.	24. As part of the scheme and artifice, Stephen Lee Seldon and Deborah			
24	Martinez Seldon jointly operated A New You in Las Vegas, Nevada, at which they offered and			
25	advertised Botox (1) injections.			
26				

Case 2:07-cr-00135-KJD-LKL

Page 7 of 13

As part of the scheme and artifice, STEPHEN LEE SELDON and Deborah 25. 1. Martinez Seldon caused advertisements to be placed in local magazines, such as "Fun & Fit", 21 "QVegas" and "The Phillipine Times," which would offer "BOTOX \$8 PER UNIT." The typical 3. advertisement, which is substantially similar to the following, would represent that: 4 "...Dr. Seldon is Board Certified and has been specially trained by Allergan for all 5 your Botox needs." 6 The typical advertisements would further state, 7[.]. "Don't be fooled by Botox prices by the 'area', wrinkles vary in size and depth. Each 8 patient at [A New You] is charged by the unit & the amount of Botox needed for their treatment. Botox is always mixed per Allergan Standards." 9 These advertisements sought to create the false impression that STEPHEN LEE SELDON was using 10 Allergan's Botox® for the treatment of his patient's wrinkles when, in fact, he was not. Π^{ij} As part of the scheme and artifice, STEPHEN LEE SELDON and 12 26. DEBORAH MARTINEZ SELDON caused Botox® promotional materials to be displayed and 13 distributed to prospective patients at A New You, when, in fact, patients were not receiving FDA-141 approved Botox®. 15 As part of the scheme and artifice, STEPHEN LEE SELDON and 27. 16 DEBORAH MARTINEZ SELDON caused a certificate to be displayed on the wall at A New You 17 which identified STEPHEN LEE SELDON as having been trained in the application of Botox®, 18 when, in fact, STEPHEN LEE SELDON had never attended any training sessions sponsored by 19 Allergan and has no Allergan-approved training in the use of Botox®. 20 As part of the scheme and artifice, STEPHEN LEE SELDON and 21 28. DEBORAH MARTINEZ SELDON caused patients to sign consent forms prior to receiving 22 cosmetic procedures. These patient consent forms fraudulently represented that the defendant 23 intended to use Botox® on the patients completing the form when, in fact, STEPHEN LEE 24 SELDON knew he was going to inject his patients with TRItox. 25 26

Case 2:07-cr-00135-KJD-LiKL

As part of the scheme and artifice, STEPHEN LEE SELDON and
 DEBORAH MARTINEZ SELDON ordered and caused to be ordered thirty-cight (38) 500 I.U. vials
 of TRItox between October 2003 and September 2004. STEPHEN LEE SELDON and DEBORAH
 MARTINEZ SELDON paid \$36,925 for a total of 19,000 units (38 vials @ 500 units per vial) of
 TRItox, approximately half of what Allergan would have charged for an equivalent amount of
 Botox[®].

30. As part of the scheme and artifice, STEPHEN LEE SELDON and
DEBORAH MARTINEZ SELDON stopped purchasing Botox® from Allergan in October 2003,
the same month they began purchasing or causing to be purchased TRItox from TRI.

10 31. As part of the scheme and artifice, STEPHEN LEE SELDON spoke at a 11 seminar in Scottsdale, Arizona, in September 2004, sponsored by TRI, in which he promoted the use 12 of TRItox and claimed that he used it on patients in his practice, notwithstanding the warning on each 13 vial that TRI was for "Research purposes only, not for human use."

14 32. In late November, 2004, the national media publicized the hospitalization of 15 four individuals who had contracted botulism after receiving injections of a non-FDA approved 16 botulinum toxin at an unrelated medical clinic in Florida. Less than two months later, in January 17 2005, as part of the scheme and artifice, DEBORAH MARTINEZ SELDON arranged for a secret 18 purchase of, and received, 132 additional vials of TRItox for \$50,000 for use by STEPHEN LEE 19 SELDON at A New You.

33. As part of the scheme and artifice, STEPHEN LEE SELDON and Deborah
Martinez Seldon failed to disclose to A New You's patients that:

22	a.	They were being injected with a different drug than Botox®;
23	b.	The product they were being injected with was not approved by the
24		FDA; and
25	c.	They were being injected with a drug labeled "For research purposes
26		only, not for human use."

Case 2:07-cr-00135-KJD-LR_ Document 1 Filed 06/27/2007 ...age 9 of 13

1	34. As pa	rt of the scheme and artifice, STEPHEN LEE SELDON and
2	DEBORAH MARTINEZ SI	ELDON took steps to conceal their fraudulent use of TRItox, as follows:
3,	а.	On or about January 12, 2005, DEBORAH MARTINEZ SELDON
4		caused to be falsified A New You's computerized medical records by
5		deleting references to "Botox®." and changing these entries to the
6		generic notation "Cosmetic Procedure;"
7	b.	On or about September 16, 2005, STEPHEN LEE SELDON and
8		DEBORAH MARTINEZ SELDON caused twenty-eight (28) vials
9		of TRItox to be returned to the FDA. STEPHEN LEE SELDON and
10		DEBORAH MARTINEZ SELDON sought to create the misleading
11 -		impression that they were returning 28 vials of the original 38 vials
12	•	purchased from TRL. In fact, STEPHEN LEE SELDON and
13		DEBORAH MARTINEZ SELDON had used all of the original
14		TRItox on the patients at A New You, and were returning vials that
15		were part of DEBORAH MARTINEZ SELDON's secret purchase of
16		132 vials from TRI in January 2005.
17	35. On or	about the dates set forth below, in the State and Federal District of
18	Nevada and elsewhere,	
19		STEPHEN LEE SELDON, MD and DEBORAH MARTINEZ SELDON,
20		JEDORAH MARTINEZ SELDOR,
21	defendants herein, aided and	abetted by each other, for the purpose of executing the scheme and
22	artifice, did knowingly cause	packages containing vials of TRItox, to be delivered by United Parcel
23	Service ("UPS"), a private and	d commercial interstate carrier, according to the directions thereon, from
24	TRI in Arizona to STEPHE	IN LEE SELDON and DEBORAH MARTINEZ SELDON in Las
25	Vegas, Nevada, as more spe	ecifically described below, with each delivery constituting a separate
26	violation of Title 18, United	States Code, Sections 1341 and 2:

Case 2:07-cr-00135-KJD-Link

Filed 06/27/2007 Page 10 of 13

1°	Γ	Count	Date of Shipment	Description of Matter Delivered	
2			by UPS	by UPS	
3			(on or about)		
4	-	1	November 15, 2003	Two vials of TRItox	
5	-	?	November 29, 2003	Two vials of TRItox	
6	2 January 10, 2004 Two yials of TRItox		Two vials of TRItox		
	4 January 31, 2004 Two vials of TRItox		Two vials of TRItox		
7	5 March 6, 2004 Two vials of TRItox		Two vials of TRItox		
8	6 March 27, 2004 Two vials of TRItox		Two vials of TRItox		
9	7 April 3, 2004 Two vials of TRItox		Two vials of TRItox		
10	8 May 1, 2004 Two vials of TRJtox		Two vials of TRJtox		
11	9 June 12, 2004 Two vials of TRItox		Two vials of TRItox		
12	10June 26, 2004Two vials of TRItox		Two vials of TRItox		
13	-	11	July 10, 2004	Two vials of TRItox	
		12	August 7, 2004	Two vials of TRItox	
14		13	August 14, 2004	Four vials of TRItox	
15	. –	14	September 18, 2004	Ten vials of TRItox	
16 17 18			<u>COUNT FIF</u> (Misbranding a Drug W	hile Held for Sale)	
19				y reference the allegations in Paragraphs (
20	through		, as though fully set forth		
21		37. Fron	n on or about October 15,	2003, and continuing through on or about	
22	September 16. 2005, in the State and Federal District of Nevada, and elsewhere,				
23			STEPHEN LEE SEL DEBORAH MARTIN	DON, MD and NEZ SELDON,	
24				جمادال المسم معمد منت المسينية والموار والم	
25	defendants herein, with the intent to defraud and mislead, did engage in various acts, and did cau				
26	each oth	her and others to en	each other and others to engage in various acts, which acts resulted in a drug being misbranded,		

Case 2:07-cr-00135-KJD-L...L

defined at 21 U.S.C. § 352(1), while such drug was held for sale after shipment in interstate 1 commerce, in that the defendants STEPHEN LEE SELDON and DEBORAH MARTINEZ 2 SELDON, offered TRItox, a drug, for sale by injection to patients under the name of a different drug, 3 Botox®, which they knew to be an FDA approved drug sold by Allergan; all in violation of 21 U.S.C. 4. §§ 331(k) and 333(a)(2) and 18 U.S.C. § 2. 5 6 . . . 7 . . . 8 . . 9 10 11 12 13 . . 14 . . . 15 . 16 . . 17 18 19 20 21 22 23 24 25 26 .

I.	FORFEITURE ALLEGATION (Mail Fraud)			
2				
3	1. The allegations contained in Counts One through Thirty-Five of this Criminal			
4	Indictment are hereby realleged and incorporated herein by reference for the purpose of alleging			
5	forfeiture pursuant to the provisions of Title 18, United States Code, Section 981(a)(1)(C) and Title			
6	28, United States Code, Section 2461(c).			
7	2. Upon a conviction of the felony offenses charged in Counts One through			
8 :	Fourteen of this Criminal Indictment,			
9	STEPHEN LEE SELDON, MD and DEBORAH MARTINEZ SELDON,			
10	DEDORAII MARTINEZ BELDON,			
11	defendants herein. shall forfeit to the United States of America any property, real or personal, which			
12	constitutes or is derived from proceeds traceable to violations of Title 18, United States Code, Section			
13	1341, a "specified unlawful activity" as defined in Title18, United States Code, Sections			
14	1956(c)(7)(A) and 1961(1)(B), up to \$144,000.00 in United States Currency.			
15	3. If any property being subject to forfeiture pursuant to Title 18, United States			
16	Code. Section 981(a)(1)(C) and Title 28, United States Code, Section 2461(c), as a result of any act			
17	or omission of the defendant -			
18	1. cannot be located upon the exercise of due diligence;			
19	2. has been transferred or sold to, or deposited with, a third party;			
20	3. has been placed beyond the jurisdiction of the court;			
21	4. has been substantially diminished in value; or			
22	5. has been commingled with other property that cannot be divided			
23 [:]	without difficulty; it is the intent of the United States of America, pursuant to Title 21, United States			
24	Code, Section 853(p), to seek forfeiture of properties of the defendant up to \$144,000.00 in United			
25	States Currency.			
26				

1	All pursuant to Title	e 18, United States Code, Section 981(a)	(1)(C), Title 28, United
2		Title 21, United States Code, Section 853	
3	DATED: this _ 27		· · · ·
4	A 'TRUE BILL:		
5			
6		/S/ FOREPERSON OF THE GRAND JU	RY
7	\land		
8	STEVEN W MYHRE		
9	Acting United States Attorney		
10	man		
11	CRANE M. IDMERANTZ		and the second
12	Assistant United States Attorney		
13			· · · · · · · · · · · · · · · · · · ·
14			
15			• • • •
16	· .		
17			
18			1
19			· . ·
20			
21			
22			and the second second second
23			· · · · · · · ·
24			
25			
26			

EXHIBIT B

Case 2:07-cr-00135-KJD-LRL

Document 150

Filed 11/20/2008

Page 1 of 2

UNITED STATES DISTRICT COURT DISTRICT OF NEVADA

UNITED STATES OF AMERICA

PLAINTIFF,

VS.

STEPHEN LEE SELDON M.D. AND DEBORAH MARTINEZ SELDON

DEFENDANTS,

2:07-CR-135-KJD-LRL

MINUTES OF THE COURT

DATED: November 19, 2008

PRESENT:

THE HONORABLE KENT J. DAWSON, UNITED STATES DISTRICT JUDGEDEPUTY CLERK: PEGGIE VANNOZZICOURT REPORTER:FELICIA ZABINPRESENT FOR PLAINTIFF:CRANE POMERANTZ AND CHRISTINA BROWN

PRESENT FOR DEFENDANTS: RONALD RICHARDS FOR STEPHEN SELDON; T. LOUIS PALAZZO FOR DEBORAH SELDON

IN COURT PROCEEDINGS: JURY TRIAL, DAY 10

Proceedings begin at 10:25 A.M. Case agent Cliff Wenzek is present. Defendants are present. The jury is present.

Mr. Palazzo presents closing argument on behalf of Defendant Deborah Martinez Seldon. Mr. Pomerantz presents the Government's rebuttal argument.

The bailiff is sworn. The jury retires to deliberate at 11:45 A.M. The alternate jurors are thanked and advised that they may be subject to recall.

Mr. Richards and Mr. Palazzo make oral Rule 29a motions and argue in support. Mr. Pomerantz responds. The Court makes findings for the record and DENIES the Rule 29a motions. Pursuant to stipulation of counsel, Defense exhibits 531 and 532 will not go to the jury.

Proceedings recess at 12:00 noon and reconvene at 2:12 P.M. Mr. Pomerantz, Mr. Richards and Mr. Palazzo are present via telephone. The Court has received a note from the jury. The Court reads the note and indicates to counsel how it intends to answer the note. Counsel do not object to the Court's answer. Proceedings recess at 2:13 P.M.

Proceedings reconvene at 5:10 P.M. The jury is present. The foreperson advises that the jury has reached a verdict. The verdict is read. The jury FINDS Defendant Stephen Lee Seldon, M.D. guilty of the offenses charged in Counts 1 through 15 of the indictment. The jury FINDS Defendant Deborah Martinez Seldon guilty of the offenses charged in Counts 1 through 15 of the indictment. The jury FINDS Defendant. The jury is polled.

The Court thanks the jurors and excuses them. The jury exits at 5:18 P.M.

Sentencing as to both defendants is set for February 19, 2009 at 9:00 A.M. Defendants are continued on personal recognizance bond, with the additional condition of travel restriction. Defendants' travel is restricted to a 300 mile radius of Las Vegas, Nevada. If Defendants have not surrendered their passports, they are to surrender

2:07-cr-135-KJD-LRL USA vs. Stephen & Deborah Seldon November 20, 2008 page two

.

their passports to Pretrial Services.

Proceedings adjourn at 5:22 P.M.

LANCE S. WILSON, CLERK U.S. DISTRICT COURT

/s/ DEPUTY CLERK

EXHIBIT C

ť

v.

BEFORE THE NEVADA STATE BOARD OF PHARMACY

NEVADA STATE BOARD OF PHARMACY,

Case No. 08-082-CS-S

Petitioner.

ORDER OF SUMMARY SUSPENSION OF CONTROLLED SUBSTANCES REGISTRATION

STEPHEN LEE SELDON, Certificate of Registration CS07633,

Respondent.

On November 18, 2008, STEPHEN LEE SELDON, M.D. was convicted in the United States District Court, District of Nevada (Case No. CR-0135-KJD-LRL) of fourteen counts of Mall Fraud and one count of Adulterating a Drug While Held For Sale all based upon Dr. Seldon's purchase and administration to patients of botulinum neurotoxin type A that was not approved by the FDA. Based upon his conviction, the Board, through its Executive Secretary Larry L. Pinson, is taking an immediate action against Dr. Seldon's controlled substances registration pursuant to NRS 639.2121. Additionally, the convictions also constitute such activity that violates NRS 639.210(4), (11), and (12) and other provisions of Nevada law as may later be determined to be applicable.

Thus, pursuant to NRS 639.2121, Dr. Seldon's controlled substances registration #CS 07633 is hereby suspended until the appropriate documents are prepared and a hearing is held before the Nevada State Board of Pharmacy pursuant to those subsequent documents. Board Staff shall prepare and file the necessary documents to assure Dr. Seldon a full and fair administrative hearing before the Board of Pharmacy after Dr. Seldon's matter is fully resolved in the federal judicial system. Dr. Seldon will be notified of the time and place of the hearing in the subsequent documents. Until the hearing before the Board of Pharmacy, Dr. Seldon may not prescribe, administer or dispense any controlled substances.

Signed and effective this 24th day of November, 2008.

Larry L. Pinson, Pharm.D., Executive Secretary Nevada State Board of Pharmacy

EXHIBIT D

Ć



COMPLAINT

The Investigative Committee of the Board of Medical Examiners of the state of Nevada, composed of Charles N. Held, M.D., Chairman, and Jean Stoess, M.A., Member, by and through Lyn E. Beggs, General Counsel for the Nevada State Board of Medical Examiners, having a reasonable basis to believe that Stephen Seldon, M.D., hereinafter referred to as Dr. Seldon, has violated the provisions of NRS Chapter 630, hereby issues its formal Complaint, stating the Investigative Committee's charges and allegations, as follows:

1. Dr. Seldon is currently licensed in active status, and was so licensed by the Nevada State Board of Medical Examiners, hereinafter referred to as "the Board," pursuant to the provisions of Chapter 630 of the Nevada Revised Statutes, at the time of the incidents in question.

2. Patient A is the patient at issue and was a forty-eight year old female at the time of the matter in question.

3. Patient A began to see Dr. Seldon in 2003 when she saw him for a cosmetic injection of Restylane. Patient A continued to see Dr. Seldon over the course of the next four years for a variety of cosmetic procedures including cosmetic injections, a combination face lift, a thread lift and a lower blepheroplasty.

26 4. Medical records for these procedures are virtually non-existent and do not accurately 27 and completely document the treatment of Patient A.

28

///

OFFICE OF THE GENERAL COUNSEL

Vevada State Board of Medical Examiner

[105 Terminal Way #30] Reno, Nevada 89502 (775) 688-2559 13

10

11

12

14

15

16

17

18

19

20

21

22

23

24

5. In October 2007, Patient A opted to undergo a tumescent liposuction treatment on a variety of areas, the majority of the liposuction to be performed in her abdominal area. On October 9, 2007 she signed a variety of waivers and a consent form regarding liposuction.

6. On October 11, 2007, Patient A presented to Dr. Seldon's office for the liposuction procedure which was begun without the use of general anesthetic or deep sedation as is standard in tumescent liposuction procedures.

7. The procedure was not completed as Patient A was apparently experiencing too much pain to continue without anesthesia and accordingly the procedure was not completed.

8. Patient A also wrote a check to Dr. Seldon for \$750 with the memo indicating it was for "Dr. Singel, Anesthesiologist." Dr. Singel is a podiatrist, not a medical doctor; however, there is no indication that Patient A was ever made aware of this fact or that she gave an informed consent to have him provide anesthesia during the procedure.

9. Patient A returned the following day, October 12, 2007 for performance of the tumescent liposuction procedure and according to the minimal medical record, "twilight" anesthesia was utilized.

10. The medical records for the procedure are minimal and are not accurate and complete.

11. Patient A was released from Dr. Seldon's office and was provided a prescription for Percocet. She was to return the following morning for a post-operative visit.

12. Patient A experienced pain and jitteriness during the night and early morning hours after the procedure and she took some of the prescribed Percocet to relieve her pain. The morning of October 13, 2007, Patient A's son phoned Dr. Seldon's office indicating that he would not be bringing in his mother as she was finally resting after a difficult night.

13. Later on October 13, 2007, Patient A's son went to Dr. Seldon's office to obtain a different pain medication for her as it was felt that the Percocet may have caused some of her jitteriness.

27 14. Patient A's son contact Dr. Seldon's office twice more on October 13, 2007, the last
28 time reporting that she was bleeding, including a large amount of blood being found in the toilet

1

2

3

4

5

6

7

8

9

18

19

20

21

22

23

24

25

15. At no time on October 13, 2007 did Dr. Seldon personally speak with Patient A's son.

16. Patient A's son and another family member eventually contacted emergency medical services and she was transported via ambulance to St. Rose Dominican Hospital where she was seen in the emergency room at approximately 7:00 p.m.

17. Patient A was admitted to the ICU where her condition worsened. She coded and although resuscitation efforts were made, she eventually died in the early morning hours of October 14, 2007.

18. An autopsy report was completed which noted the cause of death as multi-organ failure due to acute microangiopathic hemolytic anemia due to tumescent liposuction procedure. The autopsy report also noted at least thirty-five irregular and curvilinear puncture wounds on the skin on the abdomen, upper legs and buttocks. The underlying soft tissue demonstrated broad areas of hemorrhage and necrosis.

Count I

19. NRS 630.040 defines malpractice as the failure of a physician, in treating a patient, to use the reasonable care, skill, or knowledge ordinarily used under similar circumstances.

20. NRS 630.301(4) provides that malpractice is grounds for initiating disciplinary action against a licensee.

21. Dr. Seldon failed to use the reasonable care, skill, or knowledge ordinarily used under similar circumstances when he performed liposuction on Patient A utilizing a high number of incisions which is below the standard of care, and accordingly Dr. Seldon has violated NRS 630.301(4) and thus is subject to discipline.

Count II

24 22. Dr. Seldon failed to use the reasonable, care, skill, or knowledge ordinarily used 25 under similar circumstances when he allowed a podiatrist to act as anesthesiologist during the 26 procedure and did not inform Patient A of the fact that the individual was a podiatrist nor gain her 27 informed consent for him to provide the anesthesia; accordingly, Dr. Seldon has violated 28 NRS 630.301(4) and thus he is subject to discipline.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

	<u>Count III</u>
23.	NRS 630.3062(1) provides that failure to maintain timely, legible, accurate and
	dical records relating to the diagnosis, treatment and care of a patient is grounds for
•	ciplinary action against a licensee.
24.	Dr. Seldon's medical records regarding the diagnosis, treatment and care of Patient A
	lete and accurate records and include little to no information.
25.	Dr. Seldon's failure to maintain timely, legible, accurate and complete medical
records relate	ed to Patient A's care and treatment violates NRS 630.3062(1) and thus he is subject to
discipline.	
	WHEREFORE, the Investigative Committee prays:
1.	That the Nevada State Board of Medical Examiners fix a time and place for a formal
hearing;	
2.	That the Nevada State Board of Medical Examiners give Dr. Seldon notice of the
charges herei	n against him, the time and place set for the hearing, and the possible sanctions against
him;	
3.	That the Nevada State Board of Medical Examiners determine what sanctions it will
impose for th	e violation or violations committed by Dr. Seldon;
4.	That the Nevada State Board of Medical Examiners make, issue and serve on Dr.
Seldon its fir	ndings of facts, conclusions of law and order, in writing, that includes the sanctions
imposed; and	
5.	That the Nevada State Board of Medical Examiners take such other and further action
	and proper in these premises.
DATE	ED this 1^{+-} day of November, 2008.
	INVESTIGATIVE COMMITTEE OF THE NEVADA STATE BOARD OF MEDICAL EXAMINERS By: UNCOMPARING THE Investigative Committee

OFFICE OF THE GENERAL COUNSEL Nevada State Board of Medical Examiners 1105 Terminal Way #301 Reno, Nevada 89502 (775) 688-2559

۽ •...

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

VERIFICATION

STATE OF NEVADA) : ss. COUNTY OF DOUGLAS

Nevada State Board of Medical Examiners

ULLICE UL

105 Terminal Way #30 Reno, Nevada 89502 (775) 688-2559

CHARLES N. HELD, M.D., having been duly sworn, hereby deposes and states under penalty of perjury that he is the Chairman of the Investigative Committee of the Nevada State Board of Medical Examiners that authorized the complaint against the Respondent herein; that he has read the foregoing Complaint; and that based upon information discovered in the course of the investigation into a complaint against the Respondent, he believes that the allegations and charges in the foregoing Complaint against the Respondent are true, accurate, and correct.

DATED this 7th day of Normhan, 2008.

CHARLES N. HELD, M.D.